RNF43 p.G659fs 通过 PI3K/AKT/mTOR 信号通路和 HLA-E 上调导致 MSI-high 结直肠癌中 NK 细胞功能障碍
RNF43 p.G659fs leads to natural killer cell dysfunction in MSI-high colorectal cancer through PI3K/AKT/mTOR signaling and HLA-E up-regulation.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Prognostic value of fatty acid metabolism-related genes in colorectal cancer.
Prognostic value of fatty acid metabolism-related genes in colorectal cancer.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
靶向脂肪酸代谢相关基因是结肠癌(CC)的一种有前景的治疗策略,可能为个性化治疗和改善患者生存铺平道路。
结肠癌(CC)是一种全球发病率和死亡率均较高的恶性肿瘤,仍是重大的公共卫生负担。作为肿瘤代谢重编程的关键方面,脂肪酸代谢已引起广泛的研究兴趣。本研究旨在阐明脂肪酸代谢相关基因表达与CC患者预后之间的关系。
我们从癌症基因组图谱(TCGA)数据库获取了结肠癌的mRNA表达谱及相应临床信息。提取脂肪酸代谢相关基因的表达数据和生存数据用于后续分析。采用单因素Cox回归和最小绝对收缩和选择算子(LASSO)回归分析,筛选与CC患者预后相关的脂肪酸代谢相关基因。随后,基于这六个基因构建预后模型以预测生存概率。根据该模型将患者分为高风险组和低风险组。分析两组之间的差异,包括基因集富集分析(GSEA)、免疫细胞浸润、免疫治疗疗效和免疫检查点表达水平。此外,开发了一个包含风险评分、年龄、性别和临床分期的新型列线图,以预测个体患者结局。最后,使用定量实时PCR(qRT-PCR)在细胞系中验证了所识别风险基因的表达水平。
本研究共纳入449例CC样本和41例正常样本。基于6个脂肪酸代谢相关基因(ENO3、ELOVL3、ACOT11、ALAD、ELOVL6、ACADL)构建了预后模型,用于评估CC患者的预后。高风险组患者的总生存期低于低风险组(P < 0.001),AUC值为0.701。高风险组中M0巨噬细胞浸润和T辅助细胞较高,而调节性T细胞(Tregs)和NK 细胞浸润较少。高风险患者中PD-1、LAG3和CTLA4的表达水平较高,且高风险组的TIDE评分较高,提示对免疫治疗的反应较差。校准曲线、受试者工作特征(ROC)曲线和决策曲线分析(DCA)均表明,列线图方法能够准确预测CC患者的生存率。此外,qRT-PCR显示,在所有受检结肠癌细胞系中,ACOT11、ALAD和ACADL表达下调,ELOVL6和ENO3表达上调。ELOVL3在结肠癌细胞与结肠上皮细胞系之间的表达水平无显著差异。
Colon cancer (CC), a malignancy with high global incidence and mortality, remains a major public health burden. As a pivotal aspect of tumor metabolic reprogramming, fatty acid metabolism has drawn significant research interest. This study was designed to elucidate the relationship between fatty acid metabolism-related gene expression and prognosis in patients with CC. METHOD: We obtained the mRNA expression profiles and corresponding clinical information of colon cancers from The Cancer Genome Atlas (TCGA) database. Expression data of fatty acid metabolism-related genes and survival data were extracted for subsequent analysis. Univariate Cox regression and least absolute shrinkage and selection operator (LASSO) regression analyses were employed to identify fatty acid metabolism-related genes associated with prognosis in CC patients. Subsequently, a prognostic model based on these six genes was constructed to predict survival probability. Patients were stratified into high-risk and low-risk groups based on the model. Differences between the two groups were analyzed, including gene set enrichment analysis (GSEA), immune cell infiltration, immunotherapy efficacy, and immune checkpoint expression levels. Furthermore, a novel nomogram incorporating the risk score, age, gender, and clinical stage was developed to predict individual patient outcome. Finally, the expression levels of the identified risk genes were validated in cell lines using quantitative real-time PCR (qRT-PCR).
449 CC and 41 normal samples were included in this study. A prognostic model based on six fatty acid metabolism-related genes (ENO3, ELOVL3, ACOT11, ALAD, ELOVL6, ACADL) were built to evaluate the prognosis of CC patients. Patients in the high-risk group had poorer overall survival than those in the low-risk group ( P < 0.001), with AUC value of 0.701. M0 macrophage infiltration and T helper cells were higher in the high-risk group, and regulatory T cells (Tregs) and infiltration of natural killer cell (NK) cells was less. The expression levels of PD-1, LAG3, and CTLA4 were higher in high-risk patients, and the high-risk group had a higher TIDE score, indicating a worse response to immunotherapy. The Calibration plots, receiver operating characteristic (ROC) curve, and Decision Curve Analysis (DCA) all showed that the nomogram method can accurately predict the survival rate of CC patients. In addition, qRT-PCR showed downregulated expression of ACOT11, ALAD, and ACADL, and upregulated expression of ELOVL6 and ENO3 in all colon cancer cell lines tested. There was no significant difference in the expression level of ELOVL3 between colon cancer cells and colon epithelial lines.
Targeting fatty acid metabolism-related genes represents a promising therapeutic strategy for colon cancer (CC) that could pave the way for personalized treatment and enhanced patient survival.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。